source
- FDA's new rare-disease framework faces first test with Capricor's Duchenne therapy decisionThe FDA announced a new "fit-for-purpose" rare disease framework that aims to evaluate therapies based on patient need and realistically attainable evidence. The first real test of the approach wi…
- Mirum readies FDA filing after positive Phase 3 results for hepatitis D therapyMirum Pharmaceuticals announced that its hepatitis D candidate has met its primary goals in the second of two pivotal studies. The company said the data support moving the product toward regulatory…